Compare AMPL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPL | SPRY |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 914.7M | 823.2M |
| IPO Year | 2021 | 2020 |
| Metric | AMPL | SPRY |
|---|---|---|
| Price | $6.40 | $8.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $13.42 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.6M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,214,000.00 | $84,278,000.00 |
| Revenue This Year | $17.43 | $87.40 |
| Revenue Next Year | $14.16 | $81.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.68 | N/A |
| 52 Week Low | $5.51 | $6.66 |
| 52 Week High | $14.27 | $18.63 |
| Indicator | AMPL | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 53.70 |
| Support Level | $5.75 | $8.61 |
| Resistance Level | $7.73 | $9.46 |
| Average True Range (ATR) | 0.42 | 0.49 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 29.87 | 53.39 |
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.